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Introduction
Extranodal NK/T-cell lymphoma, nasal type (ENTKL), is an aggressive extranodal lymphoma of NK-cell or T-cell lineage, which is highly aggressive and has heterogenicity, with predominance in males(1-3). Current treatment strategies (such as combination chemotherapy and radiotherapy and targeted therapy) can improve the complete remission of patients, but most of them will ultimately relapse and progress (4, 5) . For these patients, standard tests, including computed tomography (CT) and serum protein markers at initial diagnosis and during routine surveillance, are pivotal for therapeutic evaluation; however, these tests have limitations with low sensitivity and specificity or false positivity. Therefore, there is an urgent need for a highly sensitive, standardized and noninvasive assay that can be used for detection of early relapse and/or progression of disease.
Current treatment response criteria for non-Hodgkin lymphoma (non-HL) rely on CT scans or positron emission tomography (PET) scans. Imaging scans at initial diagnosis or recurrence can provide macro overviews of tumor volume and location, but CT scans have some limitations due to cost and radiation exposure, and PET lacks the specificity (6) (7) (8) . Moreover, imaging scans cannot monitor dynamic tumor response and the clonal evolution process. Therefore, clinically validated technology is needed to overcome the current monitoring treatment response. One potential biomarker is the detection of circulating cell-free DNA (cfDNA), which comes from dying cells that release DNA fragments into the circulation, and in tumor patients, some of the cfDNA primarily originates from apoptotic and necrotic cancer cells, which carry tumorspecific alterations (named circulating tumor DNA, ctDNA) (9) (10) (11) (12) . ctDNA sequencing in plasma is a promising tool for real-time monitoring of tumor progression, and its application has been explored in multiple solid tumors. ctDNA can reflect the temporal evolution of tumors, so current studies have shown that ctDNA detection can be used to monitor minimal residual disease and track recurrence after treatment (13, 14) . ctDNA sequencing is a noninvasive and tumor-specific assay, and ctDNA in circulation has a half-life of less than two hours, so ctDNA is more sensitive than protein biomarkers and more specific than routine surveillance imaging with CT scans or PET scans (15) . Thus, ctDNA might become an important marker in the molecular diagnosis of tumors.
Clinical application of ctDNA has been performed in multiple types of lymphoma, such as diffuse large B-cell lymphoma (DLBCL), classical HL, follicular lymphoma and peripheral T-cell lymphoma (16) (17) (18) (19) (20) . ctDNA assessment is a prognostic tool used prior to treatment that acts as a dynamic marker of burden during treatment by using immunoglobulin next-generation sequencing (Ig-NGS), T-cell receptor gene nextgeneration sequencing (TCR-NGS) and cancer personalized profiling sequencing (CAPP-Seq). Recent evidence of ctDNA assessment in peripheral T-cell lymphoma by TCR-NGS suggested that ctDNA detection in T-lineage lymphoma is feasible (21) . In the present study, we thoroughly determined the molecular spectrum of ctDNA mutations in ENTKL and characterized the correlation between mutations in ctDNA and clinical factors. Paired tumor tissues and peripheral blood samples were collected to compare the concordance of tumor DNA and ctDNA. Moreover, dynamic ctDNA mutation alterations during the treatment were also observed.
Results

Patient characteristics
To examine the feasibility of ctDNA detection in plasma using CAPP-Seq, from February 2017 to December 2019, 65 newly diagnosed ENKTL patients were recruited, and initial and longitudinal plasma specimens were obtained from patients undergoing chemotherapy (Fig. 1 ). The median age at first blood draw was 45.2 years (range, 40 to 55 years), and 45 patients were men. At disease onset, 26 patients (40%) exhibited B symptoms. According to the Ann Arbor staging criteria, 14 patients were identified as stage I, 20 patients were identified as stage II, 13 patients were identified as stage III, and 18 patients were identified as stage IV (Table 1) . ctDNA was successfully extracted from all patients and healthy individuals, and the average concentration of ctDNA was 3.79 hEG/ml (range, 0 to 5.39 hEG/ml).
ctDNA mutation spectrum of newly diagnosed ENKTL
Of the 65 patients recruited in this study, in order to excluded hematopoietic clonal mutations, somatic mutations were observed in both plasma and PBMC were excluded, mutation were detected in the plasma of 49 (75.3%) patients with a median of 1.7 per sample (range, 0 to 19) ( Fig. 2 , upper panel). The range of mutant allele frequencies in each gene of the sample is shown in Table S1. The most frequently mutated genes were KMT2D (23.1%), APC (12.3%), ATM (10.8%), ASXL3 (9.2%), JAK3 (9.2%), SETD2 (9.2%), TP53 (9.2%), NOTCH1 (7.7%) ( Fig. 2 , middle panel).
Consistent with the somatic SNV spectrum in other tumors, we found that C>T/G>A was a preferred alteration ( Fig. 2 , lower panel).
Correlation of detectable ctDNA with clinical characteristics of ENKTL patients
To assess the concordance of the ctDNA test with the tissue NGS test, 6 paired tumor biopsies were genotyped. Compared with the results of the plasma ctDNA spectrum, most of the genes overlapped ( Fig. 3A ). In 4 patients, biopsy-confirmed tumor mutations were all detectable in ctDNA samples ( Fig. 3B ), but in patient #10, TRAF3 variation was not detected in tumor DNA. In patient #8, STAT3 could not be detected in tumor ctDNA ( Fig. 3C ). These differences might be caused by tumor anatomical heterogeneity or tumor-associated stromal tissue infiltration.
To validate the potential clinical utility of mutations detected in plasma ctDNA, we investigated the association between clinical factors and ctDNA levels. As MTV measured from PET/CT could quantitatively reflect tumor burden, we found that the plasma cfDNA concentration was significantly correlated with MTV (P=0.04) ( Fig. 4A ), suggesting that ctDNA could be identified as a promising biomarker for tumor stage and burden. In patients with stage III-IV disease, the mutation frequencies of KMT2D (11/33), ATM (5/33), JAK3 (3/33) were higher than that of patients with stage I-II disease ( Fig. 4B ). Additionally, the mutation allele frequencies of KMT2D, APC and ASXL3 were not correlated with patient stage, but the mutation frequency of ATM, JAK3 showed significant differences ( Fig. 4C ). Furthermore, the correlation of the mutation status of each gene and metabolic tumor burden was investigated. We found that patients with mutations in KMT2D, ASXL3, and JAK3 showed significantly higher metabolic tumor burden ( Fig. 4D ), suggesting that these genes might be positively correlated with disease malignancies. Recently, plasma EBV-DNA can serve as a valuable biomarker of tumor load and prognostic factor, we also evaluated the correlation between plasma EBV-DNA and clinical characteristics, we found that pretreatment plasma EBV-DNA was positively correlated with MTV ( Fig. 4E ), but the correlation of EBV-DNA levels and ctDNA concentration was not significant (Fig. 4F ).
serial ctDNA detection during therapy could complement the response assessment of the patients, and patients with mutated KMT2D and ATM predicted poor prognosis
We further investigated the potential role of plasma ctDNA in the therapeutic monitoring of patients with chemotherapy. Ten patients were recruited, sequential plasma samples at disease diagnosed, before treatment cycle 4 (C4), and before cycle 8 (C8) were collected. 7 patients could achieve CR at C4, but in these patients, only 2 couldn't detect mutation in plasma, suggesting that ctDNA assessment was more sensitivity than PET/CT scan, all patients couldn't detect plasma EBV-DNA. In addition, with more cycles of chemotherapy, all patients could achieve complete molecular remission ( Fig. 5 ). In these 10 patients, we also observed one relapsed, and the relapsed spectrum was similar with the original spectrum.
Because KMT2D was the most frequent somatic mutations, the expression of KMT2D was investigated, we found that the KMT2D expression of patients with mutated was higher than that of patients with wild type (Fig. 6A ). Next, the prognosis value of plasma ctDNA mutation status and EBV-DNA level was also investigated. Kaplan-Meier analysis estimated that patients with mutated KMT2D and ATM had a shorter OS ( Fig. 6B, 6C ), No significant difference was observed in patients with other mutated genes ( Fig. 6D-G) , which might be due to the small sample recruited in this clinical trial. In addition, patients with high EBV-DNA level showed significantly poor prognosis (Fig. 6H ). The results of univariate and multivariate analysis for risk factor of OS in patients were summarized in Tables 2. Univariate analysis of factors revealed that stage, IPI scores, recurrence status, EBV-DNA levels, KMT2D mutation and ATM mutation were independent prognostic indicators of the overall survival of patients, and multivariate analysis showed that EBV-DNA levels, KMT2D mutation and ATM mutation was solely prognostic factor. All these results suggested that dynamic detection of ctDNA during therapy could better reflect disease status compared with PET/CT scan, and patients with mutated KMT2D, and ATM predicted poor prognosis.
Discussion
This study was the first to determine the plasma ctDNA mutation gene spectrum of ENKTL using CAPP-Seq and demonstrated that ctDNA sequencing could be considered a promising biomarker for monitoring the minimal residual disease (MRD) of patients. The most frequently mutated genes in plasma ctDNA were KMT2D (23.1%), APC (12.3%), ATM (10.8%), ASXL3 (9.2%), JAK3 (9.2%), SETD2 (9.2%), TP53 (9.2%), NOTCH1 (7.7%). ctDNA concentration was positively correlated with tumor stage and MTV. Consistent with tumor tissue, almost all of the gene mutations detected in plasma ctDNA could be found in tumor DNA, and further analysis demonstrated that a decreased number and MAF of certain genes in plasma ctDNA could complement the therapeutic response of the patients, and patients with mutated KMT2D and ATM had poor prognosis, suggesting that the gene mutations in plasma could serve as a promising biomarker for the diagnosis or monitoring of ENKTL disease courses.
Tumor biopsies can only offer information about lymphoma at one specific time in a specific area and can be accompanied with complications, and PET/CT may lead to false negatives due to technology limitations or false positive caused by tumor flares or pseudoprogression (22) . ctDNA detection is an optimal noninvasive and specific technique to overcome these traditional monitoring methods. A rapidly growing body of evidence has established that ctDNA detection during curative therapies can identify patients for whom there remains evidence of residual, radiographically occult cancer. In DLBCL, ctDNA can be used to predict tumor load and treatment outcome of newly diagnosed patients, and patients with a pretreatment ctDNA level above the median had a significantly poorer prognosis than those below the median (23) . Later, Kurtz et al. reported that serial ctDNA measurements of 125 patients were an effective tool for prognostication, patients with 2-log or greater decreases in ctDNA had a better event-free survival (EFS) after one cycle of therapy, and patients with 2.5-log or greater reduction in ctDNA had a significantly better EFS after two cycle treatments. These studies suggested that serial ctDNA detection could be used to assess the therapy response dynamically and guide personalized target therapy. In another study, Daigle et al. found that mutation of CREBBP in R/R DLBCL had the greatest association with tazemetostat treatment (an EZH2 inhibitor), and patients with mutations in PIM1, BCL6, HIST1H1E and TP53 lacked response to treatment (24) . In HL, Valeria et al. determined the molecular mutation spectrum using ctDNA measurement. The most mutated genes were STAT, TNFAIP3 and ITPKB, and detection sensitivity was 87.5%, suggesting that ctDNA could reflect the spectrum of tumor tissue mutation well. Compared with newly diagnosed and refractory HL mutation profiles, most mutations overlapped, and mutations of STAT, TNFAIP3, GNA13 and ITPKB might be an ancestral clone persisted throughout disease course (20) . Although only a few studies have focused on assessing ctDNA in T-cell lymphoma, preliminary evidence has also demonstrated that ctDNA measurement in TCL is feasible (21, 25) . Our study is the first to determine the mutation spectrum of ctDNA in ENKTL. The most common mutation genes are KMT2D, APC, ATM, ASXL3, JAK3, SETD2, TP53 and NOTCH1. Our results revealed that ctDNA could reflect MTV, and by longitudinally profiling patients treated with chemotherapy, we provide evidence that serial ctDNA assessment could monitor the disease status, and the results could partially reflect which mutated gene was sensitive to chemotherapy drugs. However, only one of our 10 patients recruited for serial monitoring relapsed; for relapsed patients, whether primary mutation clone recurrence or new mutation occupies the main role needs to be further investigated. In addition, future trials should include more patients and long-term follow-up to explore the plasma gene clone evolution process.
Plasma cfDNA includes tumor cell-derived plasma ctDNA and normal cell apoptosisderived cfDNA, which are DNA fragments. ctDNA could be a more comprehensive reflection of gene mutations in all tumors than conventional biopsy (26, 27) .
Therefore, ctDNA-based detection methods are critical for identifying which mutation is tumor-specific. As sensitivity increases with the development of new methods and because age-related somatic mutations could also lead to hematopoietic clonal expansions, the possibility of false-positive results might occur (28, 29) . Recently, Razavi et al showed that clonal hematopoiesis was major contributor to plasma variants using a high-intensity sequencing assay of matched plasma DNA, tumor tissue and white blood cells, emphasizing that matched cfDNA-white blood cells was critical for screening accurate somatic mutations (30) . In the present study, to decrease the bias caused by clonal hematopoiesis associated mutations, the age range of the included patients was narrow, matched ctDNA-PBMC sample was applied, and the sequencing panel was conducted according to a previous gene-expression profiling study on ENKTL. Zhao et al. confirmed that the most frequently mutated genes in NKTCL were the RNA helicase gene DDX3X, tumor suppressors (TP53 and MGA), JAK-STAT pathway molecules (STAT3 and STAT5b) and epigenetic modifiers (MLL2, ARID1A, EP300 and ASXL3) (31) . In addition to those recurrent mutations, JAK3, KMT2D, EZH2, NOTCH1 and TET2 were also identified by different groups.
Combined with the most frequent gene mutation spectrum in Chinese individuals, we selected 41 mutated genes for our study. Interestingly, we found that KMT2D alterations possessed a higher frequency (23.1%) and which were all non-synonymous mutations (p.R2068L, p.D4378E, p.R755W, p.P2382S, p.V160L, p.L2316V).
KMT2D belongs to a family of mammalian histone H3 lysine 4 (H3K4) methyltransferase, it is frequently mutated in Kabuki syndrome and various cancers, which acts as a scaffold protein within the complex depending on cell type and stage of differentiation (32) . In acute myeloid leukemia, follicular lymphoma and DLBCL, KMT2D could inhibit tumorigenesis and metastasis (33, 34) , but in solid cancer, such as prostate cancer, KMT2D was critical factor for promoting tumor cell proliferation (35) . In our study, we found that the KMT2D expression of patients with mutated was higher than that of patients with wild type, suggesting that KMT2D might be oncogene in NKTCL lymphoma. However, the underlying significance in NKTCL has not been explored to date, and further studies regarding function of KMT2D mutation in NKTCL lymphomagenesis are urgently recommended.
To our knowledge, this is the first study to prospectively evaluate the potential utility of ctDNA analysis in NKTCL patients. We have demonstrated that ctDNA assessment could predict the therapy response in NKTCL, and the highest mutation frequencies were in KMT2D and APC. Our results could define the optimal strategy for patient follow-up.
Materials and methods
Study design and patient selection
In this prospective cohort study, 65 patients recently diagnosed with ENKTL at the hematology medical center of Xinqiao Hospital from February 2017 to December 2019 were enrolled (ClinicalTrials identifier: ChiCTR1800014813). All consecutive patients who were deemed appropriate for this study during the study period were 
Sample collection and DNA extraction
Before treatment, peripheral blood samples were collected using 10 ml EDTA vacutainer tubes and processed within 4 hours. cfDNA was extracted from plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Valencia, California) following the manufacturer's instructions. Genomic DNA was extracted from peripheral mononuclear cells and formalin fixed paraffin-embedded (FFPE) tissue.
DNA concentration and quality were estimated using a Qubit fluorometer (Invitrogen). cfDNA quality was assessed using an Agilent 2100 Bioanalyzer and DNA HS Kit (Agilent Technologies, Palo Alto, CA, USA).
Multiregional targeted NGS of patients' plasma and tumor sample
Sequencing was performed on FFPE tumor DNA, plasma cfDNA and PBMC, and targeted sequencing gene panels including coding exons and splice sites of 41 genes (Yuanqi Biopharmaceutical Co., Shanghai, China) that are recurrently mutated in NK/T-cell lymphoma were specifically designed for this study, including ADAM3A, ARID1A, ARID1B, ARID2, ASXL3, ATM, BCOR, BCORL1, CD28, CHD8,   CREBBP, DDX3X, DNMT3A, EP300, EZH2, FYN, IDH2, IL2RG, JAK1 
